Bay Area startup Cortexyme gains a $76M round to back a PhII Alzheimer's study, with a new target in their sights
With the evidence increasingly weighing in against amyloid beta as the best solo target for Alzheimer’s, a startup out of San Francisco has identified a brand new target and now has a $76 million B round to put it through its first proof-of-concept study.
The scientific inspiration for the biotech comes from UCSF psychiatrist Steve Dominy, who identified a bacterial pathogen that he believes plays a key role in the pathology of the disease. Initially working out of JLABS Bay Area facility, Cortexyme has now completed animal studies as well as a Phase I safety test to set the stage for a Phase II human study.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
